Kolon Tissuegene's Invossa(TM) starts phase 3 clinical trials starting July. It is a type of cell therapy and at the same time a gene therapy which has proven anti-inflammatory effects for osteoarthritis (abb. OA).
Kolon Tissuegene is a partly owned subsidiary of a Korean company - Kolon Life Sciences and Kolon Group. It is responsible for the development and marketing of Invossa in the Americas.
The treatment is already on the market in Korea, and those who have had the treatment report that their pain improved significantly. With a generally positive review from the patients and improving sentiments on the treatment, the treatment is expected to expand its sales ten-fold by 2020.
Since KFDA approval applies for most of Asian countries excluding China, deals to license out the treatment to other Asian countries have been on going.
This seems like good news to those in pain with OA. The company also stated, off the press that it wanted to submit a RMAT to FDA. While there was not enough evidence in the Korean clinical trials for a DMOAD, there are hints that it does indeed regenerate joint- which is the best case scenario for this company.
If it does indeed have regenerative capabilities, the cell treatment is estimated to reach around $10 billion in peak sales.
Disclaimer: This is not investment advice. This is not healthcare advice. This is just news that interests me.